Biomarker - Panitumumab Response With KRAS Wild Type MCC
NCT00853931
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
52
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Colorectal Cancer
Interventions
DRUG:
Panitumumab
Sponsor
British Columbia Cancer Agency